20 Jan 2026 | 5 Mins Read
Zydus Life eyes Ardelyx acquisition funded by QIP
Flipitmoney
Zydus Lifesciences plans to acquire a majority stake in US biopharma firm Ardelyx or purchase key molecules, raising funds through a QIP to part-fund the acquisition. Ardelyx has a $1.6 billion market capitalisation. Zydus Life's board approved a ₹5,000 crore QIP on November 6, 2025, to deleverage its balance sheet and tap into US specialty business opportunities, CNS, and cardiology spaces.